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Angiotensin II type 1 receptor gene abnonnality in a patient with
Badter's syndrome. Administration of a selective angiotensin I type 1
receptor (AT1) antagonist in animals not only nullifies the vasopressor
action of angiotensin II, but also induces chloriduria and kaliuria, juxto-
glomerular apparatus (JGA) hypertrophy and hyperreninemia, features
characteristic of human Bartter's syndrome. We, therefore, explored the
possibility that Bartter's syndrome may involve an AT1 abnormality. Using
a pair of AT1-specific oligonucleotide primers and two different DNA
polymerases (Taq and Pft), we amplified the 1 kb AT1 coding region of
genomic DNA isolated from leukocytes of five patients with Bartter's
syndrome by PCR and analyzed the sequence of the product. While the
sequence of all clones from four patients were identical to that already
reported for the normal human AT1 DNA sequence, 50% of the clones
from one patient with Bartter's syndrome were found to have A — G
transition at nucleotide 931 which causes an amino acid substitution
(arg — gly) on the carboxy-terminal cytosolic tail of AT1. This mutation
was not found in DNA from 50 normal controls which were screened by
restriction enzyme digestion pattern of the PCR products of this region.
As PCR-amplified AT1 DNA clones from four other individuals with
Bartter's syndrome did not display any abnormality in the coding region,
the possibility exists that Bartter's syndrome consists of multiple disease
entities, where an AT1 gene abnormality represents a specific subgroup of
the syndrome and/or some abnormality includes mutations outside of the
coding region.
The clinical and laboratory features of Bartter's syndrome
include a wide spectrum of fluid and electrolyte abnormalities,
such as potassium deficiency, metabolic alkalosis, hyperreninemia,
hyperaldosteronism and hyperplasia of the juxtaglomerular appa-
ratus (JGA) [1]. In view of the functional relationship among
these abnormal parameters established in the laboratory, the
pathophysiologic mechanism of the syndrome is considered a
result of a series of physiologic events derived from a single initial
pathogenic abnormality. The abnormal features can, at least in
theory, be interrelated in such multiple fashions that the chain of
events may be considered circular (Fig. 1). In this context, the
syndrome may represent multiple disease entities, in which the
series of common characteristic features originates from different
single abnormal events.
Recent endeavors in the pharmaceutical industry have pro-
duced a new class of antihypertensives, a non-peptide, orally
absorbable, specific angiotensin II type 1 receptor (AT1) antago-
nist. During the process of identifying the functional characteris-
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tics of the AT1 antagonist in experimental animals and in clinical
trials, several interesting results had been collected, which
prompted our recent study of Bartter's syndrome. Thus, acute
intravenous infusion of an AT1 antagonist but not an angiotensin
I converting enzyme inhibitor led to chloruresis in rats [21. When
given orally to normal healthy volunteers undergoing high renin
status, an AT1 antagonist caused kaliuresis [31. AT1 has also been
found to be a potent inducer for prostacycline synthesis [4].
Moreover, chronic administration of an AT1 antagonist to labo-
ratory animals has been repeatedly found by investigators to cause
a hypertrophy of the juxtaglomerular apparatus. Collectively,
experimental inhibition of AT1 has been shown to induce in
animals and/or humans several features characteristic of Bartter's
syndrome. We, therefore, ascertained the possibility that an
abnormality in the AT1 gene may be responsible for some cases of
Bartter's syndrome.
Methods
Genomic DNA samples were isolated from leukocytes obtained
from peripheral blood samples of five Japanese patients known to
have Bartter's syndrome. To determine the nucleotide sequence
of the AT1 genes of these subjects, genomic fragments were
amplified by PCR. This was done using forward and reverse
oligonucleotide primers (7CTCAACTCTFCrACTGAAGATGG29
and '°73ACCTCAAAACATGGTGCAGGCTF1051, for which
the numbers indicate the order of nucleotide from the first amino
acid-encoding nucleotide) [5]. PCR amplification products of the
expected size (—1.0 kb), including the AT1 coding exon, were
obtained using 100 pi reactions containing 200 ng nuclear DNA;
50 pmol of each primer, 0.2 mmol/liter each of deoxy-ATP, -GTP,
-CTP and -TTP; 15 mmollliter MgC12 and 2 to 5 units of Taq
DNA polymerase (Promega, Madison, Wisconsin, USA) in the
accompanying buffer with one minute denaturation at 94°C,
followed by 30 cycles of 35 seconds at 92°C (denaturation), 35
seconds at 63°C (annealing), and one minute at 72°C (extension),
finally terminating with five minutes at 72°C in a thermal cycler
(PTC100, MJ Research, Inc., Watertown, Massachusetts, USA).
The PCR products were directly cloned into a pCRII® cloning
vector (Invitrogen, San Diego, California, USA), and the nude-
otide sequence of the fragment was determined using a sequence
kit (Sequenase, U.S. Biochem. Corp., Cleveland, Ohio, USA). To
certify that the substitution was not due to a Taq polymerase
error, the experiments were repeated using P/it-DNA polymerase
(Stratagene Cloning Systems, La Jolla, California, USA), a DNA
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polymerase with the highest fidelity available commercially. Con-
ditions for PCR amplification were identical to the above except
that 54°C was chosen for the annealing temperature.
To screen genomic DNA samples from normal controls for the
specific nucleotide mutation described below, we PCR amplified a
short DNA fragment containing the site of mutation. Following
restriction endonuclease digestion, the PCR products were exam-
ined on agarose gels. However, since no restriction enzyme was
available whose digestion is affected by the A — G transition at
position 931, modification was required to enable screening PCR
products by enzyme digestion. To do this a modified primer was
used which substituted C for A at position 935. This, in conjunc-
tion with the A normally found at position 931, creates a Bgl II
recognition site (5' AGATT 3') in products from normal but not
from mutant alleles (Fig. 3A). Thus, patient and control DNAs
were PCR amplified, using a modified reverse primer, which has
G rather than T at position 935 (965GGGGGAATATAT11TA-
GAAGCTGGAGAAAAQATC932) (Note that this reverse
primer sequence represents the antisense strand, which is corn-
plementaiy to the sense strand shown in Fig. 3A) and would
anneal to mutant and normal alleles. As the 5' primer faithfully
duplicates the DNA sequence from 880th to 913rd nucleotide
(880AACAATFGCCTGAATCC1TC1Tri11ATGGC1TFC913),
the PCR products from theseS' and 3' primers are predicted to be
86 bp in length. More importantly, due to the presence versus
absence of the Bgl II recognition site, the PCR products amplified
from normal AT1 genes should yield 34 bp and 52 bp fragments
following digestion with Bgl II, whereas AT1 genes carrying the
A —+ G transition are not cleaved by Bgl II and yield only 86 bp
product following digestion. For the purpose of screening normal
controls for this mutation, genomic DNA samples were obtained
from 50 normal Japanese volunteers.
Fig. 1. Relationship between laborato,y and
clinical features characteristic of Bartter's
syndrome, including several cause-effect
relationships which are believed to be
present in the syndrome.
Results
The nucleotide sequences of the clones from four patients were
identical to that published earlier for humans. However, in one
patient, three clones out of six, generated from PCR products that
had been amplified with Taq DNA polymerase, were found to
have an A — G transition at position 931 (Fig. 2A), which causes
amino acid substitution (Arg — Gly) on the caroxy-terminal
cytosolic tail of AT1 (Fig. 2B). The A —+ G transition found at
position 952 is thought to be a polymerase error, because Dde I
recognition site ( I N A ), predicted to occur with the
mutation (C TN A ),was not detected by Dde I digestion of the
PCR products. To verit' the A — G mutation at position 931,
aliquots of genomic DNA from the same subjects were amplified
using Pfts DNA polymerase, which is known for its extremely high
fidelity. Sequence analysis on four of the clones revealed two
normal and two mutated sequences, a pattern identical to that
found with Taq DNA polymerase.
To screen genomic DNA samples from normal volunteers for
the 931 A — G mutation described above, a short fragment
including the mutation site was PCR-amplified using a modified
primer so that mutated and non-mutated sequences could be
readily recognized by the absence or presence of a Bgl II site (Fig.
3A). The analysis of the patients' genomic DNA showed three
fragment sizes (86, 52 and 34 bp; Fig. 3B), consistent with
heterozygosity for an AT1 normal allele with the Bgl II site and a
mutant allele without. The same pattern was observed following
digestion of a PCR product obtained from a 1:1 mixture of normal
and mutant cloned DNAs (Fig. 3B). In contrast, only 52 and 34 bp
fragments were observed in products of samples from 50 volun-
teers.
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Fig. 2. A. DNA sequence analyses of DNAs
cloned from PCR amplification products using
the genomic DNA of one of the five Banter's
syndrome patients as the template. An A — 0
transition was found in one allele at position
931 shown by an arrow but not in the other. B.
The pattern of the predicted hydrophobicity of
normal AT1 protein, together with an arrow
indicating the site (position 931) of the Arg —>
Gly substitution found in one patient with three
clones out of six.
Discussion
Of the five genomic DNA samples from patients with Bartter's
syndrome, one was found to have a point mutation in the
nucleotide sequence encoding the carboxy-terminal cytosolic tail
of the AT1 receptor. While we did not have the opportunity to
verify the mutation independently by analyzing samples from
family members, the abnormal sequence was demonstrated not
only by DNA sequence analysis but also by screening of PCR
amplification products by digestion with Bgl II. While both
analyses were done on the PCR amplification products obtained
using genomic DNA as templates, the products of two different
DNA polymerases used for PCR, that is, Taq and Pftt DNA
polymerases, demonstrated the identical abnormality. This
strongly indicates that the mutation represents a true abnormality
within the patient's genome. Of note, whereas 5 out of 10 clones
analyzed showed the mutation under discussion, the other 50%
had normal nucleotide sequences, indicating that the abnormality
is heterozygous in nature, that is, one allele has the coding region
mutation while the other does not.
While our preliminary site-specific mutagenesis study of AT1
cDNA expression in COS cells indicated that inositol phosphate
metabolism is indeed attenuated by the mutation, the precise
mechanism through which the observed point mutation can bring
about the clinical and laboratory features characteristic of Bart-
ter's syndrome is currently unclear. Previous deletion mutation
studies [6] suggest that the replaced amino acid is within the
portion of the AT1 protein that is involved in 0-protein coupling.
The precise mechanism by which this Arg — Gly substitution
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perturbs AT1 expression or function, however, remains unknown,
as no expression study has been heretofore conducted using a
specific point-mutant cDNA. Possible effects of the mutation on
signal transduction, or the mechanism by which AT1 dysfunction
coexists with hyperaldosteronism in the syndrome also remain
unexplained. If the hyperaldosteronism results from the hyperre-
nin-hyperangiotensin that occurs in the syndrome, the AT1 ab-
normality would be expected to result rather in hypoaldosteron-
ism, as the angiotensin Il-sensitive aldosterone secretion by the
adrenal grand is widely believed to be channelled through AT1 [7].
We consider two possibilities to reconcile these phenomena: First,
the hyperaldosteronism which occurs in Bartter's syndrome sub-
jects may not be due to a direct effect of hyperreninism, which is
a consistent finding in the syndrome. Second, it is possible that the
specific 0-proteins involved in the signal transduction of AT1
activation may differ between the vascular smooth muscle cells
and the adrenal cells. Thus, a mutation of the site for a presumed
vascular specific 0-protein coupling (such as, Arg) could conceiv-
ably impair the vascular but not adrenal receptor functions, where
the latter function is, instead, abnormally augmented due to the
hyperreninism together with the intact presumed adrenal specific
0-protein coupling site.
Fig. 3. A. The design of the modified reverse
primer used in the screening of normal
individuals for the A —* G transition at position
931. Due to this modification (A —* C) at
position 935, together with the intact A at
position 931, amplification products from
normal allele are predicted to have Bgl II site
whereas those from mutated allele are not. For
convenience of discussion, the sense strand
complementary to the antisense (reverse)
primer used in the study is presented as the 3'
primer in this figure. B. Gel patterns of PCR
amplification products using a modified reverse
primer after digestion with Bgl II. Unlike
normal controls, one patient showed a
heterozygous pattern, that is, in addition to
digested fragments of 34 and 52 bp, undigested
fragments of 86 bp were discernible on the gel.
While some cases of Bartter's syndrome are sporadic, familial
occurrences suggest that some cases are due to autosomal reces-
sive inheritance. In view of the small family size predominating in
modern society, it is conceivable that many of the sporadic cases
may be due to familial disorders in which the paucity of the
member of siblings has prevented recurrence. In this regard, the
patient found in our study to be heterozygous for a defect may
actually be a genetic compound whose other AT1 allele carries a
mutation outside the coding exon, causing such as a promoter
splicing or polyadenylation defect which perturbs AT1 expression.
In our study, only a sample from the patient's mother was
available and, in that sample, both alleles were found to have
normal exons, indicating that the patient inherited the A —* 0
transition from her father. Thus, the patient and her mother are
likely to share an unidentified mutation outside the coding exon.
If this is indeed the case, the specific site of the abnormal
mutation may be within the regulatory region for the expression of
AT1 on the vasculature (vs. adrenal). Verification of any of these
possibilities has not yet been achieved, however, due to the
unavailability of samples from other members of the family for
DNA analysis or tissue specimens from the patients for mRNA
analysis.
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Our finding of one abnormal AT1 allele in only one out of five
patients is consistent with a variety of gene abnormalities. Thus,
for example, the same disease entity could be a result of DNA
mutation at different sites, some within exon and others at cis
regulatory sequences. In this context, the possibility remains that
the four patients with the normal AT1 coding exon may also have
abnormalities outside the AT1 exons. In that case, an abnormality
in the vascular smooth muscle-specific regulatory element is,
again, an attractive possibility, as it can explain the coexistence of
the unresponsiveness to the pressor action of angiotensin II, and
the hyperrenin and hyperaldosterone status of the syndrome.
Alternatively, as discussed earlier, the abnormality in the AT1
gene may represent a subset of Bartter's syndrome, which consists
of multiple disease entities originating from different pathogenic
events. If that is the case, then elucidation of the entire patho-
physiologic spectrum of the syndrome would require examination
of multiple genes.
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